RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT03789695

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Irina Ermolaeva (from the registry)
Registry
  • NCT NCT03789695
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03789695. Randomized; no masking; primary purpose other. Start 2018-11-14 (actual); primary completion 2021-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD
Acronym
RE-ELECT
Condition
T2DM (Type 2 Diabetes Mellitus)
Condition
Chronic Kidney Diseases
Intervention (Drug)
Dabigatran Etexilate
Lead sponsor
Irina Ermolaeva (class: other)

Record details

Record id
cardio:ct-nct03789695
Content hash
f9d050e3b54281bc189cce409b05f91d5f573aebaddd209f99bc969fabc21e45